Follicular Lymphoma
📧 Sign up to get email alerts when something new happens for Follicular Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Clonal Evolution in Follicular Lymphoma
The clinical trial is currently recruiting to study clonal evolution in follicular lymphoma.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Sonrotoclax, Zanubrutinib and Rituximab in Previously Untreated Patients With Follicular Lymphoma [Phase 2]
A Phase 2 clinical trial is evaluating Sonrotoclax in combination with Zanubrutinib and Rituximab for previously untreated Follicular Lympho…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL) [Phase 2]
Phase 2 trial assessing orelabrutinib in combination with rituximab, followed by orelabrutinib maintenance, for relapsed and refractory foll…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma [Phase 1]
Phase 1 clinical trial evaluating mosunetuzumab consolidation after autologous stem cell transplantation in relapsed/refractory aggressive B…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma [Phase 2]
A Phase 2 clinical trial of XNW5004 Tablets for relapsed and refractory follicular lymphoma is currently recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies [Phase 1, Phase 2]
This is a Phase 1/2 dose-escalation and expansion study of BGB-16673 in patients with various B-cell malignancies and is currently recruitin…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial [Phase 2]
This Phase 2 trial (PROMOTE-FL) evaluates pirtobrutinib in combination with mosunetuzumab for relapsed/refractory follicular lymphoma and is…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 clinical trial update evaluating zanubrutinib in combination with sonrotoclax for relapsed or refractory B-cell non-Hodgkin lymphoma…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. [Phase 3]
A Phase 3 trial evaluating Tazemetostat in combination with Lenalidomide and Rituximab versus placebo with Lenalidomide and Rituximab in adu…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers [Phase 1]
This is a Phase 1 clinical trial update for LY4584180 in adults with previously treated blood cancers, including Non-Hodgkin lymphoma, diffu…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients [Phase 3]
Phase 3 clinical trial evaluating Surovatamig (AZD0486) in combination with Rituximab for previously untreated follicular lymphoma; currentl…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader [Phase 1, Phase 2]
Ongoing Phase 1/2 clinical trial update for BGB-16673, a BTK-targeted protein degrader, in Chinese participants with various B-cell malignan…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma [Phase 3]
Novartis is conducting a Phase 3 trial comparing tisagenlecleucel to standard of care in adults with relapsed/refractory follicular lymphoma…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma [Phase 1]
Pfizer is conducting a Phase 1 study of mevrometostat for relapsed/refractory small cell lung cancer, metastatic castration-resistant prosta…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial update describes autologous stem cell transplant followed by polatuzumab vedotin for patients with various B-cell…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma [Phase 3]
A Phase 3 trial evaluating subcutaneous epcoritamab plus intravenous rituximab and oral lenalidomide (R2) in adults with previously untreate…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma [Phase 1]
A Phase 1 trial is evaluating the addition of the immunotherapy atezolizumab to a Rituximab-Gemcitabine-Oxaliplatin regimen for relapsed/ref…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Long-term Extension Study of PCI-32765 (Ibrutinib) [Phase 3]
Phase 3 long-term extension study of ibrutinib (PCI-32765) in chronic lymphocytic leukemia/small lymphocytic lymphoma and other B-cell malig…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma [Phase 1]
This clinical trial update describes a Phase 1 study evaluating rituximab, lenalidomide, and ibrutinib in patients with previously untreated…
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008) [Phase 1, Phase 2]
This is a Phase 1/2 clinical study of MK-1045 for non-Hodgkin lymphoma, including follicular lymphoma and diffuse large B-cell lymphoma, wit…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma [Phase 1, Phase 2]
Genmab-sponsored first-in-human trial in relapsed/refractory B-cell lymphomas spans Phase 1/2 and is currently active/not recruiting.
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) [Phase 1, Phase 2]
Clinical trial update announcing a Phase 1/2 study of epcoritamab in Japanese patients with relapsed or refractory B-cell non-Hodgkin lympho…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) [Phase 1, Phase 2]
Clinical trial update on a phase 1/2 study evaluating safety and efficacy of epcoritamab combinations in adults with diffuse large B-cell ly…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma [Phase 2]
This clinical trial update reports a Phase 2 study of obinutuzumab in combination with CC-99282 for previously untreated high tumor burden f…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma [Phase 2]
Clinical trial update on a Phase II study of tazemetostat in combination with mosunetuzumab for untreated follicular lymphoma; the trial is …